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Abstract  Amyloidosis  results  from  proteins  being  deposited  as  insoluble  -pleated  sheets  and
disrupting  organ  function.  Each  precursor  protein  induces  a  separate  spectrum  of  organ  involve-
ment, and  different  disease  manifestations  within  the  lung.  Although  autopsy  ﬁndings  often
demonstrate  amyloid  deposits  in  various  compartments  of  the  lung,  few  are  manifested  patho-
logically. Amyloid  lung  nodules  with  positron  emission  tomography  (PET)  uptake  are  rare.  We
describe a  rare  case  where  PET  uptake  was  detected  in  a  pulmonary  amyloid  nodule.  To  our
knowledge there  are  six  previously  reported  cases  in  the  English  literature.
This review  also  focuses  on  amyloid  derived  from  immunoglobulin  light-chain  protein  (AL
disease), which  most  frequently  involves  the  lung  in  both  systemic  and  localized  forms  of  the
disease. Manifestations  of  AL-related  lung  disease  range  from  nodules  identiﬁed  on  inciden-
tal chest  ﬁlms  to  diffuse  alveolar  and  septal  deposition  mimicking  malignancy  and  or  diffuse
alveolar damage.
©  2011  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Nodular;
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Detecc¸ão  de  amilóide  pulmonar  nodular  por  PET  positiva  --  simulando  cancro  do
pulmão
Resumo  A  amiloidose  é  causada  por  proteínas  depositadas  como  lâminas    insolúveis  e  que
interferem  com  o  funcionamento  dos  órgãos.  Cada  proteína  precursora  induz  um  espectro  difer-emissão  positrónica
(TEP);
Amiloidose
traqueobrônquica;
Doenc¸as pulmonares
enciado de  envolvimento  dos  órgãos,  e  diferentes  manifestac¸ões  de  doenc¸a  no  pulmão.  Apesar
dos achados  de  autópsias  revelarem  frequentemente  depósitos  de  amilóide  em  vários  comparti-
mentos do  pulmão,  poucos  se  manifestam  patologicamente.  A  captac¸ão  de  nódulos  de  amilóide
do pulmão  na  tomograﬁa  de  emissão  de  positrões  (PET)  é  rara.  Descrevemos  um  caso  raro
em que  foram  detectados  nódulos  de  amiloidose  pulmonar  através  do  PET.  Que  seja  do  nosso
conhecimento,  existem  seis  casos  registados  anteriormente  na  literatura  Inglesa.
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Esta  análise  também  se  centra  na  amiloidose  derivada  da  proteína  de  cadeia  leve  de
imunoglobulina  (doenc¸a  de  AL  -- Amiloidose  primária),  que  frequentemente  envolve  o  pulmão
tanto em  formas  localizadas  como  sistémicas  da  doenc¸a.  As  manifestac¸ões  da  doenc¸a  pulmonar
relacionadas  com  a  AL  variam  desde  nódulos  identiﬁcados  em  incidências  de  raio-X  do  tórax
até à  deposic¸ão  septal,  simulando  malignidade,  e/ou  em  danos  difusos  alveolares.
© 2011  Sociedade  Portuguesa  de  Pneumologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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myloidosis  results  from  over-expression  of  speciﬁc  proteins
ulminating  in  the  extracellular  deposition  of  insoluble  -
leated  sheets  of  ﬁbers.  Initially  identiﬁed  as  carbohydrate
y  Virchow1 in  1854,  amyloid  deposits  are  composed  of  lin-
ar  arrays  of  subunit  proteins  in  glucose-aminoglycans  and
erum  amyloid  P  (SAP).
Amyloid  deposits  occur  in  systemic  and  organ-limited
orms.  In  systemic  amyloidosis,  the  composition  of  subunit
roteins  in  the  -pleated  sheets  dictates  the  pattern  of
rgan  involvement  and  disease  prognosis.  Identifying  the
ype  of  amyloidosis  strongly  impacts  the  diagnostic  differ-
ntial  of  radiographic  abnormalities.
Classiﬁcation  of  systemic  amyloidosis  is  based  on  the
ifferent  subunit  proteins,  which  deﬁne  organ  involve-
ent  and  disease  manifestations.  There  are  four  major
ategories  of  systemic  amyloidosis  (‘‘A’’  for  amyloid  and
 letter  indicating  the  protein  involved):  (1)  primary  or
mmunoglobulin  light-chain  (AL)  disease,  (2)  secondary  or
myloid  protein  A  (AA)  disease,  (3)  hereditary  or  mutant
ransthyretin  (ATTR)  disease,  and  (4)  dialysis-associated  or
2-microglobulin  (2M)  disease.  Other  less  prevalent  forms
f  amyloid  disease  exist,  locally  affecting  the  pancreas  (islet
myloid  polypeptide,  AIAPP)  and  brain  (-amyloid  precursor
rotein,  A),  or  genetically  transmitted  systemic  disease
apolipoprotein  AI,  gelsolin,  ﬁbrinogen,  lysozyme  precur-
or  proteins).  Pulmonary  manifestations  mainly  occur  from
L  disease,  this  may  be  local  or  systemic  depending  upon
he  expression  of  monoclonal  protein  either  just  locally
n  the  lung  or  in  the  serum/urine.  Amyloid  lung  nodules
ith  PET  uptake  are  rare.  We  describe  a  rare  case  where
ositron  emission  tomography  (PET)  uptake  was  noticed
n  pulmonary  amyloid  nodules.  To  our  knowledge  there
re  six  reported  cases  in  the  English  literature  to  date2--7
Table  1).
Table  1  PET  positive  cases  with  amyloid  described  in  the  literatu
Paper  Year  of
publication
Age/gender  Etiology  o
further  w
1.  Currie  et  al.  2005  73  female  r/o  ca  
2. Ollenberger  et  al.  2004  85  male  r/o  ca  
3. Umeda  et  al.  2007  60  female  r/o  ca  
4. Kung  et  al.  2003  68  female  r/o  ca  
5. Yadav  et  al.  2006  55  male  r/o  ca  
6. Grubstein  et  al. 2005  59  female  na  
r/o: rule out, na: not available.
D
W
Aase report
 68-year-old  male  with  a  past  medical  history  signiﬁcant
or  hypertension  and  osteoarthritis  presented  with  bilat-
ral  knee  pain  worse  for  the  last  few  months.  He  was  a
on-smoker,  denied  any  abuse  of  alcohol  or  any  other  illicit
ubstances.  He  had  no  known  allergies  and  his  past  surgical
istory  was  only  signiﬁcant  for  an  appendicectomy  several
ears  ago.
His  general  physical  and  systemic  examination  except  for
nee  crepitus  in  both  knees  was  otherwise  normal.  His  labo-
atory  examination  including  a  complete  blood  count,  basic
hemistry  and  liver  function  tests  including  a  clotting  proﬁle
as  normal.  No  abnormality  was  seen  on  an  electrocardio-
ram  and  pulmonary  function  tests.  On  routine  investigation
is  chest  X-ray  revealed  a  pulmonary  nodule  in  the  right
pper  lobe.  His  CT  scan  of  the  chest  (see  Figs.  1  and  2)
howed  pulmonary  nodule  2  cm  × 2 cm  in  size.
It  was  decided  to  follow  up  the  patient  with  close  mon-
toring  and  repeat  radiological  imaging.  He  was  recalled
gain  in  two  months.  Since  progression  of  the  nodules  was
uspected  (Figs.  3  and  4),  a  PET  scan  was  performed  on  this
ccasion  to  see  any  uptake  (see  Fig.  5).
Patient  underwent  an  unremarkable  bronchoscopy  and
 following  open  wedge  resection  of  the  parenchymal  lung
esion.  Pathology  revealed  deposit  of  pink  material,  double
rrows  on  either  side  of  bronchial  cartilage  (arrow)  under
ow  magniﬁcation  (see  Fig.  6)  and  further  deposits  of  amy-
oid  in  bronchial  and  alveolar  tissue  including  vessel  walls
ith  areas  of  dystrophic  ossiﬁcation.  No  malignant  cells
ere  seen  (Fig.  7  with  congo  red  stain).re.
f
orkup
Further
intervention
Video-assisted  thorascopic  wedge  biopsy
Upper  lobe  segmentectomy
Video-assisted  thorascopic  biopsy
Lung  lobectomy
Wedge  excision
na-comment:  described  2  other  cases  of  lymphoma
iscussion
hile  the  presence  of  nodular  amyloid  deposits  in  systemic
L  disease  is  controversial,  the  presence  of  nodular  amyloid
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iFigure  1  CT  on  presentation  showing  a  pulmonary  nodule
2 cm  ×2  cm  in  size.
is  well  established.  Three  forms  of  pulmonary  disease  exist
in  localized  AL  amyloid:  (1)  nodular  opacities,  (2)  diffuse
opacities,  and  (3)  tracheobronchial  disease.  A  1983  liter-
ature  review  of  localized  amyloid  lung  disease  identiﬁed
126  cases  only,  44%  having  nodular  disease,  3%  with  diffuse
opacities,  and  53%  exhibiting  tracheobronchial  amyloid.8,9
Among  these  the  presence  of  amyloid  nodules  opaci-
ﬁcation  on  chest  imaging  or  histologic  sampling  almost
uniformly  indicates  localized  disease.  The  incidence  of
nodular  disease  is  unclear  because  many  are  diagnosed  inci-
dentally  at  open  lung  biopsy  or  at  autopsy.  Among  223
autopsies  of  patients  with  amyloidosis  between  1889  and
1979,  only  three  cases  with  isolated  nodular  lung  disease
were  identiﬁed.10 Utz  et  al.11 reported  seven  cases  of  nodu-
lar  disease  over  a  13-year  period,  whereas  Hui  et  al.12
Figure  2  CT  on  presentation.  Another  level.
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rigure  3  Follow-up  CT  scan  showing  the  nodule  increase  in
ize and  with  spiculation.
escribed  25  patients  with  lung  nodules  in  the  absence  of
lasma  cell  dyscrasia.  The  lesions  range  from  0.6  to  9  cm
mean  of  3  cm)  in  size,  present  as  multiple  nodules  of  vary-
ng  size  in  58%  of  cases,  and  often  appear  peripherally  in  the
ower  lobes.12,13 The  amyloid  deposit  is  typically  surrounded
y  plasma  cells,  lymphocytes,  and  giant  cells;  small  amounts
f  amyloid  can  be  found  in  contiguous  blood  vessels.10,12
Dystrophic  calciﬁcation  and  bone  formation  were  seen  in
ver  one  third  of  lesions.6 Amyloid  nodules  grow  slowly,  if  at
ll,  and  can  cavitate.13--15 Unless  densely  calciﬁed,  all  nod-
les  should  expand  at  similar  rates.  Dyssynchronous  growth
f  one  lesion  warrants  investigation  to  rule  out  carcinoma.
ypically,  nodular  disease  does  not  impair  lung  function  nor
mpact  survivorship.12
The  pathogenesis  of  organ  involvement  in  AL  disease,
e  it  systemic  or  localized,  arises  from  the  deposition  of
onoclonal    or    immunoglobulin  (Ig)  light  chains.  In  sys-
emic  disease,  clonally  expanded  plasma  cells  residing  in
he  bone  marrow  secrete  excessive  quantities  of  monoclonal
g,  which  circulates  in  blood  to  target  organs.  Typically  AL
eposits  are  composed  of  the  variable  region  of  VI  or  I
ight-chains.  Less  commonly,  part  or  the  entire  Ig  constant
egion  is  represented.  Genotyping  of  these  two  light-chain
Figure  4  Follow-up  CT  scan  same  level  as  Fig.  2.
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oFigure  5  PET  scan:  ﬁgure  showing  uptake  co
ubgroups  suggests  that  genetic  rearrangements  may  under-
ie  production  of  amyloidogenic  proteins  in  AL  disease.
myloid  deposition  is  widespread  in  AL  disease,  although
nly  speciﬁc  organs  may  be  clinically  involved.16
Amino  acid  analyses  of  localized  amyloid  deposits
eveal  AL  protein  with  I and  III  light-chain  subgroups
redominating.17--19 In  contrast  to  systemic  disease,  mono-
lonal  proteins  constituting  localized  amyloid  deposits  arise
rom  a  small  number  of  plasma  cells  surrounding  the  lesion.
kin,  urethra  and  urinary  bladder,  eye,  larynx  and  supraglot-
ic  area,  tracheobronchial  tree,  and  lung  parenchyma  are
ites  most  commonly  involved  by  localized  amyloid.  Mono-
lonal  light-chain  does  not  circulate  or  deposit  outside  the
arget  organ.
Radiologically  among  28  cases  of  amyloid  nodules,  29%
alciﬁed  and  11%  cavitated.20,21 Pickford  et  al.22 reported
T  ﬁgures  of  ﬁve  patients  with  localized  nodular  AL;  60%
ad  one  nodule,  20%  had  two  nodules,  and  20%  had  10  nod-
les.  A  separate  series  observed  multiple  nodules  in  67%
f  the  cases.12 Eighty  percent  of  the  nodules  had  smooth
ontours  and  were  located  in  the  subpleural  region  of  the
idzone;  20%  of  the  nodules  were  spiculated.  No  asso-
iated  adenopathy  or  pleural  disease  was  detected.  With
iffuse  variety  of  AL  disease  reticular  and  reticulonodu-
ar  patterns  are  reported,12 although  peripheral  alveolar
pacities  occur  as  well.  Despite  reports  of  reticulonodular
pacities  in  localized  AL,  this  X-ray  pattern  should  prompt
horough  investigations  for  primary  systemic  (AL)  disease.
ith  tracheobronchial  variety  of  AL  disease  chest  X-rays
re  normal  in  50%  of  cases.  Findings  in  other  cases  include
telectasis  or  lobar  collapse,  calciﬁed  extraluminal  amyloid
i
r
t
honding  to  the  nodule  seen  on  CT  of  the  chest.
eposits,  bronchiectasis,  or  hilar  adenopathy.23 CT,  unlike
ronchoscopy,  demonstrates  the  full  extent  of  disease:  (a)
irway  wall  thickening,  (b)  irregular  narrowing  of  airway
umen,  and  (c)  heterotopic  calciﬁcation  of  amyloid  deposits
n  airway  walls.22--25 Additionally,  CT  depicts  airways
eyond  critical  narrowing,  affording  full  assessment  of  the
irway.
PET  imaging  is  a  useful  diagnostic  and  staging  tool  in
he  evaluation  of  suspected  or  known  carcinoma.  FDG  (18
-  ﬂuorodeoxyglucose)  enters  tumor  cells  as  a  consequence
f  increased  cellular  and  metabolic  activity.  As  with  other
iagnostic  modalities,  false  positives  can  occur  in  cases  of
uberculosis,  aspergillosis,  histoplasmosis  and  inﬂammatory
isorders.  Even  though  all  agree  the  rate  of  false  positive  is
ow  one  should  be  aware  of  other  possible  clinical  entities
hat  can  complicate  the  speciﬁcity  of  PET  scanning.26 We
cknowledge  that  FDG  as  a  radiotracer  may  be  insensitive
o  detecting  amyloid  which  would  explain  the  above  rare
nding.  Furthermore,  one  could  speculate  that  radiotracers
sed  speciﬁcally  to  detect  amyloid  e.g.  C11-PIB,  may  have
linched  the  diagnosis  but  their  current  use  is  restricted  to
esearch  settings  only.
The  published  data  addressing  prognosis  and  treatment
f  amyloid  localized  to  the  lung  are  anecdotal.  Nodular
isease  may  slowly  progress,  with  increasing  size  or  num-
er  of  lesions,  but  does  not  impact  on  lung  gas  exchange
r  patient  survival.  Diffuse  parenchymal  involvement  can
13mpair  lung  physiology  and  lead  to  death.  Rubinow  et  al.
eported  on  four  patients  with  diffuse  lung  involvement,
hree  of  whom  died  of  respiratory  failure.  Corticosteroids
ad  no  effect  on  the  course  of  disease  in  two  of  these
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Figures  6  and  7  Histology  showing  congo  red  staining  conﬁrm-
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2ing diagnosis  of  amyloid.  For  interpretation  of  the  references
to color  in  this  ﬁgure  legend,  the  reader  is  referred  to  the  web
version  of  the  article.)
patients.  Systemic  chemotherapy  is  not  advocated  for  treat-
ment  of  localized  disease;  however,  diffuse  parenchymal
involvement  may  warrant  consideration  of  aggressive  ther-
apy  given  its  inexorable  course.
Supportive  care  should  be  directed  at  minimizing  mucous
production,  which  may  further  compromise  airway  lumen
caliber.  Antibiotics,  regular  nebulizer  use,  and  occasional
courses  of  oral  or  inhaled  glucocorticoids  are  useful  adjuncts
to  airway  debridement.
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